Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Memscap
  6. News
  7. Summary
    MEMS   FR0010298620

MEMSCAP

(MEMS)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MEMSCAP EARNINGS FOR THE 2019 FISCAL YEAR: EBITDA AT EUR 1.5 MILLION FOR FY19

03/23/2020 | 02:22am EST

MEMSCAP - EARNINGS FOR THE 2019 FINANCIAL YEAR:

EBITDA AT EUR 1.5 MILLION FOR FY 19

Consolidated revenue at EUR 12.8 million for FY 19

Avionics business up +9% for FY 19

Operating profit at EUR 0.1 million - Net earnings at the break-even point

Consolidated available cash at EUR 3.4 million as of December 31, 2019

Grenoble (France) - March 23, 2020 - 07:30 AM.

MEMSCAP (NYSE Euronext: MEMS), the leading provider of innovative solutions based on MEMS (micro-electro-mechanical systems) technology, today announced its earnings for the 2019 financial year ending December 31, 2019.

Analysis of the consolidated income statement

In line with the previous quarterly press releases, MEMSCAP reported an audited revenue of EUR 12.8 million for FY 2019 compared to EUR 13.0 million for FY 2018. Expressed in US dollar, consolidated sales for FY 2019 amounted to US$ 14.3 million against US$ 15.3 million for FY 2018. It is to be noted that sales made in US dollar represented approximately 83% of the Group's revenue in 2019.

Consolidated revenue distribution by market segment, over FY 2019, is as follows:

Market segments / Revenue (In million euros)

FY 2019

%

FY 2018

%

Aerospace

6.8

53%

6.2

48%

Optical communications / Adaptive optics

3.5

27%

4.1

32%

Medical / Biomedical

1.7

13%

2.1

16%

Others

0.8

7%

0.6

4%

Total

12.8

100%

13.0

100%

(Any apparent discrepancies in totals are due to rounding.)

The continued sales growth of the avionics business was confirmed over FY 19 with an annual growth rate of +9% compared to FY 2018. The Group's avionics business accounts for more than 53% of the Group's consolidated sales for FY 2019. The optical communications business, which was impacted by trade tensions between the United States of America and China in Q3 19, reported a -15% evolution compared to FY 2018. This impact appears to be temporary since the optical communications business returned to normative sales in Q4 2019.

The increase in other activities of the Custom products division in FY 2019 offset the decrease in sales observed in the medical segment, a semi-cyclical business.

MEMSCAP's consolidated earnings for FY 2019 are given within the following table:

In million euros

FY 2019

FY 2018

FY 2018

Restated (1)

Published (1)

Revenue

12.8

13.0

13.0

Standard products*

8.5

8.3

8.3

Custom products

4.3

4.7

4.7

Cost of revenue

(8.7)

(8.5)

(8.5)

Gross margin

4.1

4.5

4.4

% of revenue

32%

34%

34%

Operating expenses**

(3.9)

(3.9)

(3.9)

Operating profit / (loss)

0.1

0.6

0.5

Financial profit / (loss)

(0.0)

0.0

0.2

Income tax expense

(0.1)

(0.3)

(0.3)

Net profit / (loss)

(0.0)

0.3

0.3

(Financial data were subject to an audit by the Group's statutory auditors who will issue their reports at a later date. On March 20th, 2020, the MEMSCAP's board of directors authorized the release of the FY 2019 consolidated financial statements. Any apparent discrepancies in totals are due to rounding.)

  • Including the royalties from the dermo-cosmetics segment.
  • Net of research & development grants.
  1. The Group has applied IFRS 16 using the full retrospective approach and the comparative information is not the same as the information previously presented in the prior year's financial statements.
    • * *

1 / 7

The financial data for the 2018 financial year and presented in the comments below have been adjusted from the restatements relating to the adoption of IFRS 16, mandatory from 1 January 2019. These "restated" financial data are therefore different from those previously "published" for the 2018 financial year. The Group has applied IFRS 16 using the full retrospective approach with restatement of comparative information. At 31 December 2019, the adoption of IFRS 16 led to an increase of EUR 5.1 million in total consolidated assets and EUR 5.7 million in total consolidated liabilities, resulting in a -EUR.0.6 million reduction in total consolidated equity. For FY 2019 and FY 2018, the adoption of IFRS 16 resulted in a non-significant reduction in net income and an increase in EBITDA of +EUR 0.5 million in these periods.

For FY 2019, the volume effect related to the activities of the Custom products division impacted the Group's gross margin rate, which stood at 32% compared to 34% for FY 2018. The consolidated gross margin thus amounted to EUR 4.1 million compared to EUR 4.5 million for FY 2018.

Operating expenses, net of research and development grants, amounted to EUR 3.9 million for FY 2019, at a similar level than FY 2018. Research and development expenses, net of grants, amounted to EUR 1.6 million for FY 2019 and represented 12% of consolidated sales (FY 2018: EUR 1.5 million / 12% of consolidated sales). Total sales and administrative expenses, at EUR 2.3 million, were slightly down compared to FY 2018 (EUR 2.4 million). In addition, the total number of full-time equivalent employees in the Group rose from 61 in FY 2018 to 65 in FY 2019, an increase of +7%.

For FY 2019, the Group posted an operating profit of EUR 0.1 million compared to an operating profit of EUR 0.6 million for FY 2018. The net financial loss for FY 2019 is not significant and included a foreign exchange gain of EUR 0.2 million, similar to the foreign exchange gain recognized in FY 2018. The tax expense recognized over FY 2019 and FY 2018 corresponded to the change in deferred tax assets related to the Norwegian and US entities of MEMSCAP. This expense had no impact on the Group's cash position.

The Group therefore reported a breakeven net result for FY 2019 compared to a net profit at EUR 0.3 million for FY 2018.

* * *

Evolution of the Group's cash / Consolidated shareholders' equity

For FY 2019, the Group posted a positive EBITDA at EUR 1.5 million compared to EUR 1.9 million for the previous year. Including the EUR 0.4 million increase in the working capital requirement, the positive cash flow from operating activities amounted to EUR 1.0 million against a cash generation of EUR 0,9 million for FY 2018. The change in the working capital requirement resulted from the ramping up of buffer stocks related to the avionics business and the reduction of trade payables at the end of FY 2019 in accordance with the material requirements planning over the year.

At December 31, 2019, the Group reported available cash at EUR 3.4 million (December 31, 2018: EUR 3.7 million) including cash investments (Corporate bonds) recorded under non-current financial assets. In addition to this amount, the available unused credit lines amounted to EUR 0.3 million at December 31, 2019.

MEMSCAP shareholders' equity totalled EUR 16.7 million at December 31, 2019. This amount is similar to the shareholders' equity reported at December 31, 2018.

* * *

Analysis and perspectives / Impact of COVID-19 pandemic

The 2019 financial year confirmed the robustness of the Group's avionics activities, up +9% compared with FY 2018 and now representing more than 53% of the annual consolidated revenue. This evolution compensated the temporary reduction of the optical communications business, previously affected by trade tensions between the United States of America and China.

Regarding the COVID-19 pandemic, the Group's production sites located in Norway and the United States (North Carolina) remain operational. The Group is currently assessing the impacts of this pandemic.

MEMSCAP pursues its strategy focused on avionics, medical and optical communications segments, backed by its own intellectual property, as well as the development of an increased flexibility of its production capacities.

* * *

Q1 2020 earnings: April 27, 2020

Annual meeting of shareholders: May 28, 2020

2 / 7

About MEMSCAP

MEMSCAP is the leading provider of innovative micro- electro-mechanical systems (MEMS)-based solutions.

MEMSCAP's products and solutions include components, component designs (IP), manufacturing and related services.

Contacts

Yann Cousinet

Chief Financial Officer Ph.: +33 (0) 4 76 92 85 00 yann.cousinet@memscap.com

For more information, visit our website at:

www.memscap.com.

MEMSCAP is listed on Euronext Paris ™ - Segment C - ISIN: FR0010298620 - MEMS.

MEMS

3 / 7

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

at 31 December 2019

31 December

31 December

2019

2018

Restated (1)

€000

€000

Assets

Non-current assets

Property, plant and equipment......................................................................................

1 757

1 794

Goodwill and intangible assets.......................................................................................

7 804

7 908

Right-of-use assets .........................................................................................................

5 934

6 316

Other non-current financial assets.................................................................................

1 254

1 309

Deferred tax asset ..........................................................................................................

412

541

17 161

17 868

Current assets

Inventories .....................................................................................................................

3 111

2 807

Trade and other receivables...........................................................................................

2 938

2 943

Prepayments ..................................................................................................................

186

280

Other current financial assets ........................................................................................

47

35

Cash and short-term deposits ........................................................................................

2 204

2 380

8 486

8 445

Total assets

25 647

26 313

Equity and liabilities

Equity

Issued capital..................................................................................................................

1 867

1 867

Share premium...............................................................................................................

18 775

18 775

Treasury shares ..............................................................................................................

(131)

(130)

Retained earnings ..........................................................................................................

(1 204)

(1 199)

Foreign currency translation ..........................................................................................

(2 601)

(2 641)

16 706

16 672

Non-current liabilities

Lease liabilities ...............................................................................................................

5 685

5 977

Interest-bearing loans and borrowings ..........................................................................

127

236

Employee benefit liability...............................................................................................

56

20

5 868

6 233

Current liabilities

Trade and other payables ..............................................................................................

2 083

2 297

Lease liabilities ...............................................................................................................

588

589

Interest-bearing loans and borrowings ..........................................................................

324

444

Provisions .......................................................................................................................

78

78

3 073

3 408

Total liabilities

8 941

9 641

Total equity and liabilities

25 647

26 313

  1. The Group has applied IFRS 16 using the full retrospective approach and the comparative information is not the same as the information previously presented in the prior year's financial statements.

4 / 7

CONSOLIDATED STATEMENT OF INCOME

For the year ended 31 December 2019

Continuing operations

Sales of goods and services ..............................................................................................

Revenue.....................................................................................................................

Cost of sales......................................................................................................................

Gross profit................................................................................................................

Other income....................................................................................................................

Research and development expenses ..............................................................................

Selling and distribution costs............................................................................................

Administrative expenses...................................................................................................

Operating profit / (loss) .............................................................................................

Finance costs ....................................................................................................................

Finance income.................................................................................................................

Profit / (loss) for the year from continuing operations before tax.................................

Income tax expense..........................................................................................................

Profit / (loss) for the year from continuing operations ...............................................

Profit / (loss) for the year...........................................................................................

Earnings per share:

  • Basic, for profit / (loss) for the year attributable to ordinary equity holders of the parent (in euros).........................................................................................................
  • Diluted, for profit / (loss) for the year attributable to ordinary equity holders of the parent (in euros) ..................................................................................................

2019

€000

  1. 779
  1. 779

(8 720)

4 059

497 (2 077)

(766) (1 581)

132

(185)

157

104

(136)

(32)

(32)

  • (0.004)
  • (0.004)

2018

Restated (1)

€000

  1. 961
  1. 961

(8 493)

4 468

527 (2 030)

(725) (1 680)

560

(178)

212

594

(330)

264

264

  • 0.036
  • 0.036
  1. The Group has applied IFRS 16 using the full retrospective approach and the comparative information is not the same as the information previously presented in the prior year's financial statements.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the year ended 31 December 2019

2019

2018

Restated (1)

€000

€000

Profit / (loss) for the year..........................................................................................

(32)

264

Items that will not be reclassified subsequently to profit or loss

Actuarial gains / (losses) .................................................................................................

(69)

(30)

Income tax on items that will not be reclassified to profit or loss..................................

--

--

Total items that will not be reclassified to profit or loss ............................................

(69)

(30)

Items that may be reclassified subsequently to profit or loss

Net gain / (loss) on available-for-sale financial assets....................................................

95

(171)

Exchange differences on translation of foreign operations............................................

40

(35)

Income tax on items that may be reclassified to profit or loss.......................................

--

--

Total items that may be reclassified to profit or loss .................................................

135

(206)

Other comprehensive income for the year, net of tax ...............................................

66

(236)

Total comprehensive income for the year, net of tax ................................................

34

28

  1. The Group has applied IFRS 16 using the full retrospective approach and the comparative information is not the same as the information previously presented in the prior year's financial statements.

5 / 7

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 31 December 2019

(In thousands of euros, except for number of shares)

Number

Issued

Share

Treasury

Retained

Foreign

Total

of shares

capital

premium

shares

earnings

currency

shareholders'

translation

equity

€000

€000

€000

€000

€000

€000

At 1 January 2018 Restated (1).............................................................

7 246 190

1 812

18 770

(126)

(1 242)

(2 606)

16 608

Profit for the year.................................................................................

--

--

--

--

264

--

264

Other comprehensive income for the year, net of tax.........................

--

--

--

--

(201)

(35)

(236)

Total comprehensive income ...........................................................

--

--

--

--

63

(35)

28

Capital increase ....................................................................................

222 150

55

5

--

(54)

--

6

Treasury shares ....................................................................................

--

--

--

(4)

--

--

(4)

Share-based payment ..........................................................................

--

--

--

--

34

--

34

At 31 December 2018 Restated (1) .......................................................

7 468 340

1 867

18 775

(130)

(1 199)

(2 641)

16 672

At 1 January 2019 Restated (1).............................................................

7 468 340

1 867

18 775

(130)

(1 199)

(2 641)

16 672

Loss for the year...................................................................................

--

--

--

--

(32)

--

(32)

Other comprehensive income for the year, net of tax.........................

--

--

--

--

26

40

66

Total comprehensive income ...........................................................

--

--

--

--

(6)

40

34

Treasury shares ....................................................................................

--

--

--

(1)

--

--

(1)

Share-based payment ..........................................................................

--

--

--

--

1

--

1

At 31 December 2019 ......................................................................

7 468 340

1 867

18 775

(131)

(1 204)

(2 601)

16 706

(1) The Group has applied IFRS 16 using the full retrospective approach and the comparative information is not the same as the information previously presented in the prior year's financial statements.

6 / 7

CONSOLIDATED CASH FLOW STATEMENT

For the year ended 31 December 2019

2019

2018

Restated (1)

€000

€000

Cash flows from operating activities:

Net profit / (loss) for the year ............................................................................................

(32)

264

Non-cash items written back:

Amortization and depreciation ....................................................................................

1 247

1 199

Loss / (capital gain) on disposal of fixed assets............................................................

35

(16)

Other non-financial activities.......................................................................................

87

344

Accounts receivable ...........................................................................................................

(49)

(90)

Inventories .........................................................................................................................

(274)

(312)

Other debtors.....................................................................................................................

16

(176)

Accounts payable ...............................................................................................................

(72)

(326)

Other liabilities ...................................................................................................................

(6)

21

Total net cash flows from operating activities .............................................................

952

908

Cash flows from investing activities:

Purchase of fixed assets .....................................................................................................

(388)

(644)

Proceeds from sale / (purchase) of financial assets ...........................................................

118

(276)

Total net cash flows from investing activities ..............................................................

(270)

(920)

Cash flows from financing activities:

Repayment of borrowings..................................................................................................

(108)

(106)

Payment of lease liabilities.................................................................................................

(573)

(581)

Sale / (purchase) of treasury shares...................................................................................

(2)

(4)

Proceeds from issue of shares............................................................................................

--

6

Total net cash flows from financing activities ..............................................................

(683)

(685)

Net foreign exchange difference........................................................................................

(53)

(1)

Increase / (decrease) in net cash and cash equivalents ................................................

Opening cash and cash equivalents balance ................................................................

Closing cash and cash equivalents balance ..................................................................

(54)

  1. 044
  1. 990

(698)

  1. 742
  1. 044
  1. The Group has applied IFRS 16 using the full retrospective approach and the comparative information is not the same as the information previously presented in the prior year's financial statements.

7 / 7

Disclaimer

Memscap SA published this content on 23 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 March 2020 07:21:10 UTC


ę Publicnow 2020
All news about MEMSCAP
10/26GLOBAL MARKETS LIVE : Michelin, Facebook, UBS, Tesla, Volvo...
10/26MEMSCAP, S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2021
CI
09/01GLOBAL MARKETS LIVE : Getlink, Intuit, CrowdStrike, Xiaomi, Merck...
08/31MEMSCAP – FIRST HALF 2021 EARN : Positive operating cash flow at +1.0 million euros
PU
07/27MEMSCAP Q2 2021 : Significant growth in sales of the group's avionics business despite an ..
PU
05/28MEMSCAP : Minutes of the annual ordinary and extraordinary shareholders' meeting
PU
05/28MEMSCAP : Proxy Statments
CO
04/27GLOBAL MARKETS LIVE : Tesla, UBS, Novartis...
04/27Memscap, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
04/27MEMSCAP : 1st quarter earnings
CO
More news
Financials
Sales 2020 11,1 M 12,6 M 12,6 M
Net income 2020 -0,55 M -0,62 M -0,62 M
Net Debt 2020 3,55 M 4,02 M 4,02 M
P/E ratio 2020 -16,6x
Yield 2020 -
Capitalization 10,9 M 12,3 M 12,3 M
EV / Sales 2019 1,36x
EV / Sales 2020 1,13x
Nbr of Employees 64
Free-Float 89,8%
Chart MEMSCAP
Duration : Period :
Memscap Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEMSCAP
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Jean-Michael Karam Chairman & Chief Executive Officer
Yann Cousinet Chief Financial Officer
Nicolas Bertsch COO & GM-Custom Products Business Unit
JoŰl Rodriguez Alanis Independent Director
Bernard Courtois Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MEMSCAP15.23%12
MEDIATEK INC.42.57%58 030
SKYWORKS SOLUTIONS, INC.-0.80%25 083
SANAN OPTOELECTRONICS CO., LTD.24.84%24 654
UNIGROUP GUOXIN MICROELECTRONICS CO., LTD.73.53%22 014
SILERGY CORP.93.15%15 897